The Novel Cardiovascular Therapeutics Summit 2017 is a unique meeting dedicated to translating the latest developments in the genomic and molecular understanding of the causes of cardiovascular disease, heart failure and cardiomyopathy into new pharmacological therapies in the clinic.
With an agenda driven by scientific sessions, case studies and clinical data, this meeting will address your major challenges in preclinical and clinical cardiovascular research to achieve safer, faster and more cost-effective cardiovascular drug development.
Join the conversation with fellow academics, researchers and biopharmaceutical industry leaders at the forefront of cardiovascular drug development in a collaborative effort to drive translational research in this field forward.
“The overall quality of speakers was excellent. It’s rare to have strategic leaders all in one room comparing notes.”
Douglas Losordo, CMO, Caladrius Biosciences